Quest PharmaTech Inc QPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CAD 0.04
- Day Range
- CAD 0.02–0.02
- 52-Week Range
- CAD 0.02–0.11
- Bid/Ask
- CAD 0.02 / CAD 0.04
- Market Cap
- CAD 3.38 Mil
- Volume/Avg
- 7,000 / 16,083
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- http://www.questpharmatech.com
Valuation
|
Metric
|
QPT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.05 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
QPT
Financial Strength
|
Metric
|
QPT
|
|---|---|
Quick Ratio | 0.26 |
Current Ratio | 0.26 |
Interest Coverage | −1,081.54 |
Quick Ratio
QPT
Profitability
|
Metric
|
QPT
|
|---|---|
Return on Assets (Normalized) | −1.99% |
Return on Equity (Normalized) | −2.01% |
Return on Invested Capital (Normalized) | −1.96% |
Return on Assets
QPT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xsdlrqzwb | Plb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dkqwcqsrr | Ztqhqs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ktzcmpdm | Syxpl | $97.8 Bil | |
MRNA
| Moderna Inc | Thqskndz | Phtky | $41.3 Bil | |
ARGX
| argenx SE ADR | Sljvdhhtg | Wbll | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xmsjmjvl | Ybff | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mfqvmvd | Pjsljd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zsnlshl | Mypngx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yryqzbfq | Qdwbln | $12.5 Bil | |
INCY
| Incyte Corp | Jdxtlyxwq | Mmmvn | $11.6 Bil |